在2型糖尿病患者中使用SGLT2抑制剂的短期实验室结果:回顾性分析
Hamood AlSudais1, Turky AlSulaiman2, Badi A Alotaibi3,4
1Chair of Medical and Molecular Genetics Research, Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 12372, Saudi Arabia.
Journal of clinical medicine
|November 27, 2025
概括
达帕格利弗洛辛显著改善了2型糖尿病 (T2DM) 患者的血糖控制. 此外,SGLT2抑制剂在6个月内改变了主要的血液,和肝脏标志物.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 对达帕格利弗洛辛在2型糖尿病 (T2DM) 的短期效果的回顾性评估.
- 专注于六个月治疗期间的实验室标记物变化.
研究的目的:
- 评估Dapagliflozin对T2DM患者的血糖,血液,脏和肝脏标记物的影响.
- 为了确定治疗反应中的潜在基于性别的差异.
主要方法:
- 783名成年T2DM患者的电子健康记录的回顾性分析.
- 达帕格利弗洛辛治疗开始前和开始治疗后六个月进行的实验室检测.
- 统计分析以确定各种实验室参数的显著变化.
主要成果:
- 在血糖标志物中观察到显著的减少 (p<0.01).
- 根据性别的不同血液学趋势:女性增加MCHC和RDW,男性减少MCH;两者的MCV下降.
- 脏变化包括的增加,男性的eGFR降低,男性和女性的BUN升高. 在肝脏标志物中观察到ALP的边际增加和AST的减少 (男性).
结论:
- 达帕格利弗洛辛在T2DM患者的血糖控制中显著改善.
- 治疗导致血液学,脏和肝脏实验室标记物的显著变化.
- 需要进一步的研究来阐明机制和长期影响.
相关概念视频
Oral Hypoglycemic Agents: Glinides
573
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
573
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Dipeptidyl Peptidase 4 Inhibitors
566
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
566
Oral Hypoglycemic Agents: Biguanides and Glitazones
567
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
567
Glucose Transporters
27.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
509


